Mergers & Acquisitions Mergers & Acquisitions

CSL seeks EU clearance for $11.7 billion Vifor Pharma deal

By Andrew Boyce
  • 27 Apr 2022 15:05
  • 27 Apr 2022 15:05
CSL, an Australian biotechnology company, has filed its $11.7 billion acquisition of Vifor Pharma for EU review.
The European Commission has set an initial June 3 deadline to decide on the deal.

CSL describes itself as a leading biotechnology company with a portfolio of life-saving medicines, including to treat hemophilia

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Andrew Boyce


Andrew is a reporter covering merger reviews and competition policy for MLex in Brussels. He joined MLex in 2015 and holds a degree and a master’s degree in history from the University of Liverpool.

Discover MLex

Stay on top of global regulatory developments

Latest News